| Vol. 14.03 – 27 January, 2022 |
| |
|
|
| Researchers unveiled the ectonucleotide pyrophosphatase /phosphodiesterase 1 (ENPP1)/Haptoglobin axis as an unanticipated mechanism exploited by tumor cells linking inflammation to immune remodeling favoring local relapse. [Cancer Discovery] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A single therapeutic was developed based on trastuzumab-conjugated nanoparticles for co-delivering docetaxel and siRNA against human epidermal growth factor receptor type 2 (HER2+). [Small] |
|
|
|
| Investigators revealed a novel oncogenic function of IKBKE in promoting breast cancer metastasis by governing Snail abundance, and highlighted the potential of targeting IKBKE for metastatic breast cancer therapies. [Cell Death & Differentiation] |
|
|
|
| Restoring SELENOF could attenuate a number of aggressive cancer phenotypes in breast cancer cells, including clonogenic survival, and enhanced the response to drugs or radiation used in breast cancer therapy. [Oncogene] |
|
|
|
| Scientists found that the low expression of RICH1 in breast cancer was associated with poor prognosis. Depletion of RICH1 promoted the stemness and disrupted the normal epithelial architecture of MCF10A cells. [Cell Death & Disease] |
|
|
|
| Investigators used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in breast cancer (BC) and revealed that YTHDF1 could serve as a new molecular marker for BC immunotherapy. [Scientific Reports] |
|
|
|
| Tamoxifen (TAM) is a selective estrogen receptor modulator with potential clinical benefits for all stages of breast cancer. The authors reported novel TAM analogues that could avoid metabolism via CYP2D6. [Chemmedchem] |
|
|
|
| Investigators developed a novel pH-responsive modified chitosan-based nanoparticles system for active loading of doxorubicin and triggered intracellular release. The cytotoxic effects of these nanoparticles were performed against the MCF-7 BrCA cell line under different pHs. [Current Cancer Drug Targets] |
|
|
|
| Scientists investigated the cellular activities of α-mangostin, human cancer cells, MCF-7, and MCF-7-CR cells by treating them with α-mangostin to measure the cellular responses, including cytotoxicity, protein-protein interaction, and protein expression. [Evidence-Based Complementary and Alternative Medicine] |
|
|
|
| Researchers investigated the nuclear peroxisome proliferator-activated receptor gamma-dependent proliferation behavior of breast cancer cells after stimulation with matcha green tea extract. [Archives of Gynecology and Obstetrics] |
| |
|
|
|
| The authors report the prognostic value, clinical relevance, and biological significance of the Nischarin gene in breast cancer patients using the Molecular Taxonomy of Breast Cancer International Consortium and The Cancer Genome Atlas datasets. [Oncogene] |
|
|
|
| Scientists specifically review the data for the management of HER2+ parenchymal brain metastases and provide an overview of ongoing clinical trials which include patients with HER2+ brain metastases. [CNS Drugs] |
|
|
|
|
| ORIC Pharmaceuticals, Inc. announced clearance of its Clinical Trial Application by the regulatory authorities of the Republic of Korea for ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations. [ORIC Pharmaceuticals, Inc.] |
|
|
|
|
| March 9 – 11, 2022 Melbourne, Victoria, Australia |
|
|
|
|
|
| University of Bristol – Bristol, United Kingdom |
|
|
|
| The Wistar Institute – Philadelphia, Pennsylvania, United States |
|
|
|
| Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| Charity-University Medicine Berlin – Berlin, Germany |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|